StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.10−0.08 (-6.78%)

Close on Nov 16, 2026Market cap $14.67MP/E –Yield 0.00%

Tvardi Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Tvardi Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.01M, down 19.3% year over year. For fiscal 2025 it was $18.01M, down 23.8% from the year before. Over ten years it grew -1.6% a year on average. The highest annual figure on record is $113.82M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.01M-23.8%
FY2024Dec 31, 2024$23.65M-78.2%
FY2023Dec 31, 2023$108.51M+18.1%
FY2022Dec 31, 2022$91.88M+11.1%
FY2021Dec 31, 2021$82.70M-23.3%
FY2020Dec 31, 2020$107.85M-5.2%
FY2019Dec 31, 2019$113.82M+50.7%
FY2018Dec 31, 2018$75.53M+55.7%
FY2017Dec 31, 2017$48.52M-1.5%
FY2016Dec 31, 2016$49.25M+132.1%
FY2015Dec 31, 2015$21.22M+40.8%
FY2014Dec 31, 2014$15.07M+73.5%
FY2013Dec 31, 2013$8.69M+88.9%
FY2012Dec 31, 2012$4.60M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.00M-31.1%
Q1 FY2026Mar 31, 2026$4.91M+57.9%
Q4 FY2025Dec 31, 2025$5.49M-36.2%
Q3 FY2025Sep 30, 2025$3.60M-24.9%
Q2 FY2025Jun 30, 2025$5.81M-11.1%
Q1 FY2025Mar 31, 2025$3.11M-85.8%
Q4 FY2024Dec 31, 2024$8.60M-69.7%
Q3 FY2024Sep 30, 2024$4.80M-81.2%
Q2 FY2024Jun 30, 2024$6.53M-78.5%
Q1 FY2024Mar 31, 2024$21.96M-9.7%
Q4 FY2023Dec 31, 2023$28.42M+9.2%
Q3 FY2023Sep 30, 2023$25.45M+3.1%
Q2 FY2023Jun 30, 2023$30.31M+52.3%
Q1 FY2023Mar 31, 2023$24.33M+14.4%
Q4 FY2022Dec 31, 2022$26.01M+13.9%
Q3 FY2022Sep 30, 2022$24.69M+59.2%
Q2 FY2022Jun 30, 2022$19.91M-21.1%
Q1 FY2022Mar 31, 2022$21.27M+11.2%
Q4 FY2021Dec 31, 2021$22.83M-15.9%
Q3 FY2021Sep 30, 2021$15.51M-26.4%
Q2 FY2021Jun 30, 2021$25.23M-3.4%
Q1 FY2021Mar 31, 2021$19.13M-43.0%
Q4 FY2020Dec 31, 2020$27.14M-9.1%
Q3 FY2020Sep 30, 2020$21.07M-41.5%
Q2 FY2020Jun 30, 2020$26.11M+7.2%
Q1 FY2020Mar 31, 2020$33.54M+42.1%
Q4 FY2019Dec 31, 2019$29.86M+31.0%
Q3 FY2019Sep 30, 2019$35.99M+61.4%
Q2 FY2019Jun 30, 2019$24.36M+43.3%
Q1 FY2019Mar 31, 2019$23.61M+75.8%
Q4 FY2018Dec 31, 2018$22.80M+97.0%
Q3 FY2018Sep 30, 2018$22.30M+143.7%
Q2 FY2018Jun 30, 2018$17.00M+144.2%
Q1 FY2018Mar 31, 2018$13.43M-35.6%
Q4 FY2017Dec 31, 2017$11.58M-42.9%
Q3 FY2017Sep 30, 2017$9.15M-5.4%
Q2 FY2017Jun 30, 2017$6.96M–
Q1 FY2017Mar 31, 2017$20.84M–
Q4 FY2016Dec 31, 2016$20.28M–
Q3 FY2016Sep 30, 2016$9.67M–

More Tvardi Therapeutics figures

See a number that looks wrong?